Workflow
禽流感药物
icon
Search documents
华润三九涨2.05%,成交额2.96亿元,主力资金净流入1944.70万元
Xin Lang Zheng Quan· 2025-10-10 03:40
机构持仓方面,截止2025年6月30日,华润三九十大流通股东中,香港中央结算有限公司位居第二大流 通股东,持股4361.40万股,相比上期增加705.16万股。华泰柏瑞沪深300ETF(510300)位居第四大流 通股东,持股1193.47万股,相比上期增加356.72万股。易方达沪深300医药ETF(512010)位居第五大 流通股东,持股1096.93万股,相比上期增加185.89万股。易方达沪深300ETF(510310)位居第七大流 通股东,持股848.71万股,相比上期增加261.73万股。中欧医疗健康混合A(003095)退出十大流通股 东之列。 华润三九所属申万行业为:医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括:维生素、禽流感药物、医药 电商、抗流感、化妆品等。 截至9月20日,华润三九股东户数10.04万,较上期增加6.25%;人均流通股16561股,较上期减少 5.88%。2025年1月-6月,华润三九实现营业收入148.10亿元,同比增长4.99%;归母净利润18.15亿元, 同比减少24.31%。 分红方面,华润三九A股上市后累计派现100.69亿元。近三年,累计派现49.15亿元。 1 ...
生物股份涨2.18%,成交额6400.81万元,主力资金净流入129.77万元
Xin Lang Cai Jing· 2025-09-26 02:56
Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown a significant increase of 30.31% year-to-date, despite a recent decline of 1.11% over the past five trading days [1][2] Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1] - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1] Financial Performance - For the first half of 2025, the company reported an operating income of 620 million yuan, reflecting a year-on-year growth of 1.28%. However, the net profit attributable to shareholders decreased by 50.84% to 60.42 million yuan [2] - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 54,900, with an average of 20,405 circulating shares per person, a decrease of 3.70% from the previous period [2] - The top ten circulating shareholders include notable ETFs, with the Guotai Zhongzheng Livestock Breeding ETF holding 15.95 million shares, an increase of 648,300 shares from the previous period [3]
太龙药业跌2.12%,成交额8473.54万元,主力资金净流出65.07万元
Xin Lang Cai Jing· 2025-09-25 06:43
Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.12% on September 25, with a current price of 6.46 CNY per share and a market capitalization of 3.707 billion CNY [1] Company Overview - TaiLong Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, is located in Zhengzhou, Henan Province. The company operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The revenue composition of TaiLong Pharmaceutical includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of June 30, 2025, the number of shareholders is 40,900, a decrease of 11.14%, with an average of 14,037 circulating shares per person, an increase of 12.53% [2] Financial Performance - For the first half of 2025, TaiLong Pharmaceutical reported a revenue of 762 million CNY, a year-on-year decrease of 17.77%, and a net profit attributable to shareholders of 19.35 million CNY, down 27.32% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.53 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the seventh largest circulating shareholder is Guangfa Pension Index A, holding 3.236 million shares as a new shareholder, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF has exited the top ten circulating shareholders [3]
浙江医药涨2.07%,成交额1.26亿元,主力资金净流入1276.54万元
Xin Lang Zheng Quan· 2025-09-24 05:43
Core Viewpoint - Zhejiang Medicine's stock price has shown a decline of 7.58% year-to-date, with a recent increase of 2.07% on September 24, 2023, indicating potential volatility in the market [1]. Financial Performance - For the first half of 2025, Zhejiang Medicine reported a revenue of 4.323 billion yuan, a year-on-year decrease of 1.87%, while the net profit attributable to shareholders was 673 million yuan, reflecting a significant increase of 113.52% [2]. - Cumulative cash dividends since the company's A-share listing amount to 4.377 billion yuan, with 661 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 65,500, with an average of 14,674 circulating shares per person, a decrease of 0.55% [2]. - The top circulating shareholder, Hong Kong Central Clearing Limited, holds 71.2904 million shares, an increase of 34.9417 million shares compared to the previous period [3].
普莱柯跌2.04%,成交额1528.26万元,主力资金净流入18.87万元
Xin Lang Cai Jing· 2025-09-23 02:24
Core Viewpoint - The stock price of Pulaike has experienced fluctuations, with a year-to-date increase of 8.94% but a recent decline over various trading periods, indicating potential volatility in the market [2]. Company Overview - Pulaike Bioengineering Co., Ltd. is located in Luoyang, Henan Province, established on June 22, 2002, and listed on May 18, 2015. The company primarily engages in the research, production, and sales of veterinary biological products, chemical drugs, and traditional veterinary medicine [2]. - The revenue composition of Pulaike includes: poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2]. Financial Performance - For the first half of 2025, Pulaike achieved operating revenue of 559 million yuan, representing a year-on-year growth of 15.79%. The net profit attributable to the parent company was 116 million yuan, reflecting a significant increase of 57.12% [2]. - Since its A-share listing, Pulaike has distributed a total of 1.057 billion yuan in dividends, with 500 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Pulaike had 18,000 shareholders, an increase of 4.27% from the previous period. The average circulating shares per person decreased by 4.09% to 19,234 shares [2]. - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF ranks as the seventh largest, holding 3.4499 million shares, an increase of 141,400 shares from the previous period [3].
海正药业跌2.05%,成交额1.11亿元,主力资金净流出236.83万元
Xin Lang Cai Jing· 2025-09-19 03:21
Group 1 - The core viewpoint of the news is that Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has experienced fluctuations in its stock price and financial performance, with a notable decline in net profit despite a slight increase in revenue [1][2]. - As of September 19, the stock price of Hai Zheng Pharmaceutical fell by 2.05% to 10.52 CNY per share, with a total market capitalization of 12.612 billion CNY [1]. - The company has seen a year-to-date stock price increase of 29.96%, but it has declined by 1.13% in the last five trading days and 7.80% in the last 20 days [1]. Group 2 - Hai Zheng Pharmaceutical's main business segments include pharmaceutical manufacturing, with a revenue composition of 39.38% from pharmaceutical commerce, 18.26% from anti-infection drugs, and 13.01% from cardiovascular drugs [1]. - For the first half of 2025, the company reported a revenue of 5.250 billion CNY, reflecting a year-on-year growth of 0.13%, while the net profit attributable to shareholders decreased by 31.29% to 299 million CNY [2]. - The company has distributed a total of 1.726 billion CNY in dividends since its A-share listing, with 445 million CNY distributed in the last three years [3].
南新制药跌2.06%,成交额3119.68万元,主力资金净流出417.11万元
Xin Lang Cai Jing· 2025-09-19 02:14
Company Overview - Nanjing Pharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on December 27, 2006. The company was listed on March 26, 2020. Its main business focuses on the research, production, and sales of antiviral drugs for influenza and other infectious diseases, as well as treatments for major diseases such as cardiovascular diseases and diabetes. The revenue composition is 100% from chemical drug formulations [1][2]. Stock Performance - As of September 19, the stock price of Nanjing Pharmaceutical decreased by 2.06%, trading at 12.37 CNY per share, with a total market capitalization of 3.394 billion CNY. The stock has increased by 89.14% year-to-date, but has seen a decline of 4.70% over the last five trading days and 14.81% over the last 20 days [1]. - The company has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on August 27, where it recorded a net purchase of 104 million CNY [1]. Financial Performance - For the first half of 2025, Nanjing Pharmaceutical reported a revenue of 61.8463 million CNY, a year-on-year decrease of 71.28%. The net profit attributable to the parent company was -40.0023 million CNY, reflecting a year-on-year decrease of 493.23% [2]. - The company has distributed a total of 40.74 million CNY in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 7.02% to 9,464, while the average circulating shares per person decreased by 6.56% to 28,994 shares [2]. - Among the top ten circulating shareholders, Dazheng Jingheng Mixed A (090019) holds 2.9738 million shares, with no change in the number of shares held compared to the previous period [3].
众生药业涨2.19%,成交额1.57亿元,主力资金净流出216.00万元
Xin Lang Cai Jing· 2025-09-18 02:14
Company Overview - Zhongsheng Pharmaceutical Co., Ltd. is located in Dongguan, Guangdong Province, established on December 31, 2001, and listed on December 11, 2009. The company focuses on the research, production, and sales of pharmaceuticals [1]. - The main business revenue composition includes: Traditional Chinese Medicine sales 53.03%, chemical drug sales 38.12%, Chinese medicinal materials and decoction pieces sales 6.13%, raw materials and intermediates sales 2.14%, and others 0.58% [1]. Financial Performance - For the first half of 2025, Zhongsheng Pharmaceutical achieved operating revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%. However, the net profit attributable to the parent company was 188 million yuan, showing a significant year-on-year increase of 114.96% [2]. - Since its A-share listing, the company has distributed a total of 2.019 billion yuan in dividends, with 502 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 18, the stock price of Zhongsheng Pharmaceutical increased by 2.19%, reaching 20.54 yuan per share, with a total market capitalization of 17.458 billion yuan [1]. - The stock has seen a year-to-date increase of 71.88%, with a recent 5-day increase of 1.68%, a 20-day decrease of 8.95%, and a 60-day increase of 36.48% [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on July 29, where it recorded a net purchase of 181 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 89,900, a decrease of 1.32% from the previous period, with an average of 8,470 circulating shares per person, an increase of 1.33% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 9.1731 million shares, while other notable shareholders include Xingquan He Feng Mixed Fund and Xingquan Multi-Dimensional Value Mixed Fund, which have reduced their holdings [3].
普莱柯跌2.07%,成交额3212.20万元,主力资金净流出65.95万元
Xin Lang Cai Jing· 2025-09-16 02:48
Company Overview - Pulaike Bioengineering Co., Ltd. is located in Luoyang, Henan Province, established on June 22, 2002, and listed on May 18, 2015. The company primarily engages in the research, production, sales, and related technology transfer of veterinary biological products, chemical drugs, and traditional veterinary medicine [1][2]. Financial Performance - For the first half of 2025, Pulaike achieved operating revenue of 559 million yuan, representing a year-on-year growth of 15.79%. The net profit attributable to the parent company was 116 million yuan, reflecting a significant increase of 57.12% [2]. - Since its A-share listing, Pulaike has distributed a total of 1.057 billion yuan in dividends, with 500 million yuan distributed over the past three years [3]. Stock Performance - As of September 16, Pulaike's stock price decreased by 2.07% to 14.21 yuan per share, with a total market capitalization of 4.918 billion yuan. The stock has seen a year-to-date increase of 14.92%, but has declined by 1.93% over the last five trading days and 6.76% over the last twenty days [1]. - The stock's trading volume on September 16 was 32.122 million yuan, with a turnover rate of 0.65% [1]. Shareholder Information - As of June 30, 2025, Pulaike had 18,000 shareholders, an increase of 4.27% from the previous period. The average circulating shares per person decreased by 4.09% to 19,234 shares [2]. - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF (159865) ranked as the seventh largest, holding 3.4499 million shares, an increase of 141,400 shares from the previous period [3]. Business Segments - Pulaike's main business revenue composition includes: poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [1].
金河生物跌2.08%,成交额9664.34万元,主力资金净流出1044.35万元
Xin Lang Cai Jing· 2025-09-16 02:48
Company Overview - Jinhe Biology Co., Ltd. is located in Inner Mongolia and was established on March 14, 1990, with its listing date on July 13, 2012 [2] - The company specializes in the production, sales, research, and service of animal health products, with a revenue composition of 61.83% from veterinary chemical drugs, 19.76% from starch and related products, 11.12% from veterinary vaccines, 4.97% from environmental services, and 2.15% from other sources [2] Financial Performance - For the first half of 2025, Jinhe Biology achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45%, and a net profit attributable to shareholders of 138 million yuan, up 51.52% year-on-year [2] - The company has distributed a total of 877 million yuan in dividends since its A-share listing, with 227 million yuan distributed over the past three years [3] Stock Performance - As of September 16, Jinhe Biology's stock price was 7.05 yuan per share, with a market capitalization of 5.44 billion yuan [1] - The stock has increased by 61.22% year-to-date, with a recent 5-day increase of 1.29%, a 20-day decrease of 5.87%, and a 60-day increase of 12.44% [1] - The company has appeared on the trading leaderboard six times this year, with the most recent occurrence on April 16, where it recorded a net buy of -28.30 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 104.38% to 64,500, while the average circulating shares per person decreased by 51.07% to 11,547 shares [2] - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF is the third-largest shareholder, holding 7.66 million shares as a new investor [3]